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Vancomycin (VAN) is the gold standard therapy for Methicillin-resistant Staphylococcus aureus (MRSA) 
infections such as bacteremia and endocarditis. However, VAN suboptimal dosing for serious infections 
caused by S. aureus isolates that have elevated minimum inhibitory concentration (MIC), could be 
associated with poor outcome. Better understanding of VAN pharmacokinetics and pharmacodynamics 
(PK/PD) has led to the creation of new recommendations with optimized dosing regimens for the 
treatment of MRSA infections. For severe infectious, such as pneumonia and endocarditis, a VAN 
serum trough concentration of 15–20 mg/L at the steady state should be targeted. The aim of this study 
was to show how a nomogram with updated VAN dosing was devised and how it was implemented 
in the electronic prescribing (e-prescribing) system of a teaching hospital. VAN loading dose and 
maintenance doses were calculated from a pharmacokinetic equation using basic parameters: weight, 
estimated creatinine clearance, as well as peak and trough serum concentrations. The implementation of 
the VAN dosing nomogram in the hospital e-prescribing system definitively changed the long-standing 
medical prescription fallacy of “same dose fits all”. Finally, this computer-based electronic program has 
allowed a wide-ranging intervention and should be recognized as a powerful tool for implementation in 
antimicrobial stewardship programs.
Uniterms: Vancomycin/prescribing. Methicillin/use. Staphylococcus aureus/methicillin-resistant. 
Electronic prescribing system/application in hospital. Antibiotics/rational use. Antimicrobials/rational use.
Vancomicina (VAN) é utilizada como primeira escolha na terapia de infecções causadas por 
Staphylococcus aureus resistentes à meticilina (MRSA), como bacteremia e endocardite. Entretanto, o 
aumento na concentração inibitória mínima (CIM) de isolados de S. aureus e doses subterapêuticas de VAN 
podem estar associados à falha terapêutica. Para o melhor entendimento sobre o perfil farmacocinético 
e farmacodinâmico (PK/PD) da VAN foram elaboradas novas recomendações para terapia de infecções 
causadas por MRSA. Para terapia de infecções graves, como pneumonia e endocardite, a concentração 
sérica do vale de VAN de 15-20 mg/L no estado de equilíbrio dinâmico deve ser o alvo. O objetivo do estudo 
foi desenvolver um nomograma com doses atualizadas de VAN e demonstrar como ele foi implementado 
no sistema de prescrição eletrônica em um Hospital Universitário. As doses de ataque e manutenção foram 
calculadas a partir de equações farmacocinéticas, utilizando parâmetros fundamentais: peso, depuração 
de creatinina, concentrações séricas do pico e do vale. A implementação de um nomograma de doses de 
VAN em um sistema de prescrição eletrônica modificou definitivamente o inadequado hábito de que “a 
mesma dose cabe em todos”. Finalmente, esta abrangente ferramenta tecnológica deve ser considerada 
como uma robusta estratégia num programa de uso racional de antibióticos.
Unitermos: Vancomicina/prescrição. Meticilina/uso. Staphylococcus aureus/resistência à meticilina. 
Sistema de prescrição eletrônica/aplicação em hospitais. Antibióticos/uso racional. Antibacterianos/
uso racional.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus 
(MRSA) is a major pathogen in hospital-acquired 
infections worldwide and, in some countries, has also 
become an emergent pathogen in community-acquired 
infections (David, Daum, 2010).
Alternative antimicrobial agents with proven 
efficacy against MRSA infections, such as linezolid, 
daptomycin and tigecycline, are available. However, 
except for daptomycin, these drugs are not FDA approved 
for the treatment of bacteremia and endocarditis. 
Vancomycin (VAN) remains the most widely used drug in 
clinical practice for MRSA infections and is comparatively 
less costly (Liu et al., 2011).
Better knowledge about VAN pharmacokinetics/
pharmacodynamics (PK/PD) has allowed proposals 
to optimize VAN dosing. AUC24h/MIC (area under the 
plasma-concentration curve in 24 hours divided by the 
minimal inhibitory concentration) has been considered 
in animal models, and in a study involving humans 
with pneumonia caused by S. aureus, as the most 
representative PK/PD index for VAN. The study in 
humans showed that clinical outcome and bacteriological 
eradication were superior in patients who attained 
the VAN PK/PD index of ≥ 400 AUC24h/MIC (Moise-
Broder et al., 2004). In addition, for S. aureus with VAN 
MIC of 1 mg/L, the AUC24h of 400 would be necessary 
to reach the recommended PK/PD index of 400. It is 
noteworthy that for S. aureus with MIC > 1 mg/L VAN, 
a higher dosing regimen would be necessary to achieve 
the recommended PK/PD target and the benefits of this 
are uncertain. Therefore, in this scenario, alternative 
drugs should be considered because of increased risk 
of VAN toxicity and clinical failure. The VAN serum 
trough concentration of 15 mg/L or greater is correlated 
to an AUC24h of around 400, and higher doses are usually 
necessary to attain this target (Rybak et al., 2009). 
Based on these data, the Infectious Diseases Society of 
America (IDSA) and American Society of Health-System 
Pharmacists guidelines have updated VAN dosing 
to 15–20 mg/kg every 8–12 hours targeting a trough 
serum concentration of 15 to 20 mg/L for the treatment 
of severe infections such as pneumonia, endocarditis, 
osteomyelitis and meningitis in adult patients (Rybak et 
al., 2009; Liu et al., 2011).
An electronic prescribing (e-prescribing) system is a 
technology that improves the quality of patient care and the 
safety of medication management by decreasing medical 
errors through the feature of electronically sending an 
accurate and understandable prescription directly to a 
pharmacy from the point-of-care. Utilization of electronic 
systems and e-prescribing in antibiotic stewardship 
programs are an encouraging innovative field but with 
limited reports to date (Tamma, Cosgrove, 2011).
The aim of this study was to show how a nomogram 
with an updated VAN dosing regimen for adults was 
devised using a linear PK model and how it was 
implemented in an e-prescribing system.
MATERIAL AND METHODS
This study is a report of the VAN nomogram 
calculation with individualized PK parameters, and how it 
was subsequently implemented. The study was conducted 
in a public teaching hospital with 300 beds for adult 
patients located in Rio de Janeiro city. The hospital utilizes 
the MedTrak systems, an integrated Electronic Medical 
Record and Medical Practice Management Software 
Service that allow electronic prescribing and many 
electronic surveillance tools including microbiological 
culture results, MRSA chart flagging, notification of 
new orders for VAN prescriptions and, since 2010, 
the provision of antibiotic dosing regimen orientation 
through e-prescribing. For the development of the VAN 
dosing nomogram, a one-compartment model (the Bauer 
model) was used. Individualized parameters were applied 
in the equations to calculate the VAN maintenance 
dose regimens with the following PK parameters: 
VAN clearance (Clvanco), volume of distribution (Vd), K 
elimination (K), half-life (t1/2) and dosing interval (DI).
Total body weight in kg (TBW) and estimated creatinine 
clearance in mL/min (ClCr) were stratified into ranges. 
For the dose calculations, the midpoint of each range 
was used to estimate the most adequate dose regimen 
for each patient category. For example, in patients in the 
TBW range of 71–80 kg and renal function with ClCr in 
the 50–59 mL/min range, the values used in the equation 
were 75 kg and 55 mL/min, respectively. For patients with 
ClCr ≥ 120 mL/min, the value used was 130 mL/min. The 
ClCr was calculated using the Cockcroft and Gault (1976) 
formula. VAN loading dose was calculated independently 
of renal function by multiplying TBW by 25 mg. The ClCr 
calculation and pharmacokinetic equations along with the 
variables employed are shown below:
Estimated creatinine clearance
ClCr (mL/min) = (140 – A) x W / SCr x 72. For females, the 
final product is multiplied by 0.85.
VAN clearance
Clvanco (mL/min/kg) = 0.695 x (ClCr/TBW) + 0.05
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Volume of distribution
Vd (L) = 0.7 x TBW
Elimination rate constant
K (h-1) = Clvanco / Vd
Half-life
t1/2 (h) = 0.693 / K
Dosing interval
DI (h) = ln Peakd – ln Troughd / K
Maintenance dose
MD (mg) = Peakd x Vd x [1 - e - (K x DI)]
Symbol key: A represents age in years, W represents 
weight in kg, SCr represents serum creatinine in mg/
dL, TBW represents total body weight, while Peakd and 
Troughd represent desired VAN serum peak and trough 
concentrations both in mg/L.
Peak and trough concentrations of VAN were 
selected as 50 mg/L and 17.5 mg/L, respectively. This 
trough serum level is to achieve empirical optimal 
exposure to S. aureus with VAN MIC ≤ 1 mg/L according 
to MRSA VAN MIC distribution (MIC90) from clinical 
samples obtained at our hospital. VAN infusion rate was 
applied according to doses: 60 minutes of infusion for 
doses ≤1.0 g, 90 minutes for 1.1 to 1.5 g, 120 minutes for 
1.6 to 2.0 g, and for doses >2.0 g the infusion rate was 
around 1.0 g/h.
The dosing intervals were planned to reduce the 
unnecessary risk of developing toxicity by exposure to 
high doses (for instance 1.0 g q6h as opposed to 2.0 g 
q12h) and to guarantee obtention of the desired trough 
level. Dosage regimens were rounded according to VAN 
dose vial (500 mg) and to facilitate drug scheduling 
for nursing (6, 8, 12, 24, and 96 h). For patients on 
hemodialysis (i.e. ClCr<10 mL/min) the recommend drug 
interval was 4 days. It is important to consider that in this 
hospital, patients are submitted to hemodialysis using the 
low-flux dialyzer and that VAN removal by this type of 
dialyzer is negligible regardless of blood or dialysate flow. 
For patients whose weight was under 50 kg or over 100 kg, 
it is recommended that assistance be sought to calculate 
VAN dosing individually.
RESULTS AND DISCUSSION
The VAN dosing nomogram for adults according 
to TBW and ClCr is shown in Table I. The nomogram 
includes six weight ranges from ≥ 50 to ≤ 100 kg and 
11 renal function ranges from patients on dialysis with 
ClCr<10 mL/min to patients with ClCr>120 mL/min.
The computer based program with the nomogram is 
accessed when VAN is typed into the e-prescribing sheet by 
the physician. The nomogram dosing adjustment window 
with the requested parameters is then automatically 
triggered (Figure 1). The prescriber must input values for 
the variables TBW and ClCr into the window for automatic 
display of the VAN dosage regimen and rate of infusion. 
For the beginning of therapy, the system automatically 
marks the option of loading dose, whereas for subsequent 
days the option of loading dose is left unmarked by default. 
TABLE I - Vancomycin dosing nomogram for adults according to total body weight and renal function
Weight 
(kg)
Loading 
Dose
Maintenance Dose
Estimated Creatinine Clearance (mL/min)
< 10 10 - 19 20 - 29 30 - 39 40 - 49 50 - 59 60 - 69 70 - 79 80 - 99 100 - 119 ≥ 120
50-60 1500 mg 1000 mg q96h
500 mg 
q24h
750 mg 
q24h
500 mg 
q12h
500 mg 
q12h
750 mg 
q12h
750 mg 
q12h
1000 mg 
q12h
1250 mg 
q12h
1750 mg 
q12h
1750 mg 
q12h
61-70 1500 mg 1250 mg q96h
500 mg 
q24h
750 mg 
q24h
500 mg 
q12h
750 mg 
q12h
750 mg 
q12h
1000 mg 
q12h
1250 mg 
q12h
1000 mg 
q8h
1750 mg 
q12h
1250 mg 
q8h
71-80 2000 mg 1250 mg q96h
500 mg 
q24h
1000 mg 
q24h
750 mg 
q12h
750 mg 
q12h
1000 mg 
q12h
1000 mg 
q12h
1500 mg 
q12h
1000 mg 
q8h
1250 mg 
q8h
1000 mg 
q6h
81-90 2000 mg 1500 mg q96h
750 mg 
q24h
1250 mg 
q24h
750 mg 
q12h
1000 mg 
q12h
1000 mg 
q12h
1250 mg 
q12h
1500 mg 
q12h
1750 mg 
q12h
1000 mg 
q6h
1000 mg 
q6h
91-100 2250 mg 1750 mg q96h
750 mg 
q24h
1250 mg 
q24h
750 mg 
q12h
1000 mg 
q12h
1250 mg 
q12h
1500 mg 
q12h
1500 mg 
q12h
1000 mg 
q6h
1000 mg 
q6h
1000 mg 
q6h
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Updated renal function is notified by the electronic system 
for daily e-prescribing. For patients on hemodialysis, the 
prescriber must check the first box at the top (Patients on 
hemodialysis) then the ClCr of 9.0 mL/min is selected 
automatically. For better control of the VAN prescription, 
a tool in the electronic chart that includes patient weight 
and height has been created. These patient parameters 
are displayed at the top right of the prescription sheet 
(Figure 1) allowing easy visual checking and when 
necessary, dose revision.
Severe infections caused by MRSA have to be 
promptly treated with the right choice of antimicrobial 
and dosing to achieve optimal drug exposure. Owing to 
increased MICs for VAN, more-intensive VAN dosing 
schedules have to be administered. VAN 1.0 g q12h 
has been the standard dose regimen prescribed in our 
institution. There was a pressing need to definitively 
change this old practice of “same dose fits all”, and 
therefore we decided to devise an updated VAN nomogram 
and implement this in the e-prescribing system. To our 
knowledge, this is the first report of a VAN dosing regimen 
nomogram implemented in an e-prescribing system at a 
Brazilian hospital.
Several VAN PK models, such as Matze, Birt, 
Ambrose, Burton and Bauer methods based on linear 
regression, and Bayesian estimations based on nonlinear 
regression, have been created to estimate the PK 
parameters of VAN to facilitate the initial drug dosing 
calculations. Although Bayesian PK models offer the 
advantage of calculating VAN dosing for a population 
database through the use of two or three compartment 
equations, these models are not widely used in the 
clinical field. They are also complex models that demand 
specialized PK knowledge and costly computer programs 
(Bauer, 2008).
We chose the Bauer method, a linear regression 
model that applies individualized PK equations and allows 
simplified and accurate VAN dosage calculations. In this 
method, the utilization of intravenous bolus constitutes a 
limitation. However, VAN elimination during intravenous 
infusion is poor and PK equations that consider the loss 
of drug during the infusion time are not obligatory, 
as intravenous bolus equations can predict VAN peak 
concentration (Bauer, 2008).
According to recent guidelines and other experts, 
the desirable VAN serum trough concentration should be 
in the 15 to 20 mg/L range (Rybak et al., 2009; Liu et al., 
2011). Considering the recommendation of a loading dose, 
a study showed that patients with a ClCr 80 mL/min who 
have received a VAN dose of 15 mg/kg q12h without a 
loading dose, only 23% achieved the desired serum target 
at 36 h (Drusano et al., 2007). In 2011, IDSA guidelines 
for MRSA therapy included the recommendation to 
administer a VAN loading dose of 25-30 mg/kg (TBW) 
in seriously ill patients with a limit of 2-g per dose (Liu 
et al., 2011). In the present nomogram, a loading dose of 
FIGURE 1 - Vancomycin e-prescribing chart sheet and window with requested patient parameters. Subtitle: Peso is Weight, Altura 
is Height. Dados complementares para o uso de antibióticos is Additional data for antibiotic dosing, Paciente em hemodiálise is 
Patient on hemodialysis, Clearance de creatinina is Estimated creatinine clearance, Dose de ataque? is loading dose?
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2.250 mg was recommended for patients with a TBW of 
91-100 kg.
It is relevant to ponder that in severe infections 
during the first hours of therapy when the bacteria burden 
is high, and while the host still has to mount an appropriate 
immune response, the antibiotics should be as effective 
as possible during this critical period, justifying more 
intensive VAN dosing. Nonetheless, there is a genuine 
concern over VAN-induced nephrotoxicity by dose 
maximization (van Hal, Paterson, Lodise, 2013).
In 2010, as a part of the antibiotic stewardship 
program, the VAN nomogram was implemented into 
the Medtrak e-prescribing system. This program has 
promoted an immediate impact on patient VAN dosage 
needs, increasing the probability of obtaining an initial 
optimal VAN dose. In a recent study, the applications 
of VAN nomograms showed that target serum VAN 
concentration were achieved in a higher number of 
patients with optimized dose regimen (Kullar et al., 2011). 
One considerable limitation of the present study is that 
the nomogram has yet to be validated and VAN serum 
concentration monitoring is necessary for the adjustment 
of maintenance doses.
CONCLUSION
The implementation of a VAN nomogram in a 
computer-based electronic program allowed a wide-
ranging intervention in patient care with an immediate 
impact on updating VAN dosing that should be recognized 
as a powerful tool in antimicrobial stewardship programs.
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